India Anemia Drugs Market Analysis Report 2022 to 2030

India Anemia Drugs Market Analysis

$ 3999

India's Anemia drugs market was valued at $291 Mn in 2022 and is estimated to expand at a CAGR of 11.9% from 2022-30 and will reach $714 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories among others.

ID: IN10INPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Nandini Shah

Buy Now

India Anemia Drugs Market Executive Summary

The India Anemia drugs market was valued at $291 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.9% from 2022 to 2030 and will reach $714 Mn in 2030. Anemia is a medical disorder when the hemoglobin or red blood cell (RBC) level is below normal. Some of the most common indications and symptoms of Anemia include fatigue, shortness of breath, dizziness, and palpitations. In 2018, the Government of India launched the Anaemia Mukt Bharat (AMB) strategy, with the goal of reducing anemia in vulnerable age groups such as women, children, and adolescents through a life cycle approach that includes 6 target beneficiaries, 6 interventions, and 6 institutional mechanisms for all stakeholders to implement the strategy.

According to the National Family Health Survey (2019-21), the prevalence of anemia among 6 groups is 25% percent in men (15-49 years) and 57% percent in women (15-49 years). 31% among adolescent boys (15-19 years old), 59.1% among adolescent girls, 52.2% among pregnant women (15-49 years old), and 67.1% among toddlers (6-59 months).

Market Dynamics

Market Growth Drivers

The prevalence of anemia in India is quite high, which is driving the demand for anemia drugs in the country. With rising income levels and improved healthcare infrastructure, the spending on healthcare is increasing, which is expected to boost the demand for anemia drugs in India. The government of India has been implementing various awareness and screening programs for anemia, such as Anemia Mukh Bharat which are increasing the diagnosis and treatment rates of anemia, thus driving the demand for anemia drugs. With the growing aging population in India, the incidence of anemia is increasing, which is expected to drive the demand for anemia drugs in the country. 60+ population is predicted to grow by more than 320 million over a 50-year period, from 2011 to 2061. In percentage terms, this translates to an increase in India's old population from 8.6% in the 2011 census to 12.5% by 2030, nearly 20% by 2050, and slightly more than 25% by 2061. The development of new and improved anemia drugs, such as erythropoietin-stimulating agents (ESAs) and iron supplements, is expected to drive the growth of the anemia drugs market in India.

Market Restraints

While there are awareness programs for anemia, a large part of the population is still not aware of the condition, its symptoms, and the available treatments. This could limit the demand for anemia drugs in India. India's healthcare infrastructure is inadequate, particularly in rural areas, which could limit access to anemic drugs for those who need them. Over 75% of healthcare infrastructure is concentrated in metro cities, which have only 27% of the overall population—the remaining 73% of Indians lack even basic medical amenities. Over 3,000 doctors are needed in primary care centers, and the shortage has expanded by 200 percent in the last decade. Some of the issues that require immediate addressing are the government's healthcare spending, the demand-supply mismatch, and persistent shortages. According to data, India has 1.4 beds for every 1,000 people, 1 doctor for every 1,445 people, and 1.7 nurses for every 1,000 people. India is a price-sensitive market, and the affordability of drugs is a major concern. Anemia drugs may not be affordable for many of those who need them, which could limit demand and market growth.

Competitive Landscape

Key Players

Sun Pharmaceutical Industries
Cipla
Dr. Reddy's Laboratories
Torrent Pharmaceuticals
Alkem Laboratories
Takeda Pharmaceutical
Eli Lilly and Company
Abbott

Healthcare Policies and Regulatory Landscape

The Central Drug Standards Control Organization (CDSCO), part of the Directorate General of Health Services (Ministry of Health & Family Welfare), is India's major regulatory authority for medical devices and diagnostics. The Drug Controller General of India is the CDSCO's top officer (DCGI). The DCGI is in charge of overseeing the approval of specific pharmaceuticals (vaccines, large volume parenteral, blood products, r-DNA derived goods), medical devices, and novel drugs. The Drugs and Cosmetics Act and Rules oversee the manufacture, import, sale, and distribution of medical equipment in India (DCA).

Reimbursement Scenario

The Insurance Regulatory and Development Authority (IRDAI) has mandated that all health insurance companies offer mandatory Arogya Sanjeevani coverage by April 2020. The policy would cover up to Rs 5 lakh - 10 lakhs for essential healthcare services, but it will not cover advanced treatments, transplants, or urgent procedures. The Authority's authorities and functions are outlined in the IRDAI Act of 1999 and the Insurance Act of 1938. The IRDAI's primary goals include promoting competition in order to improve customer happiness through expanded consumer choice and fair pricing, while also maintaining the financial soundness of the insurance sector.

The Insurance Act of 1938 is the primary Act governing India's insurance sector. It gives IRDAI the authority to draught regulations that establish the regulatory framework for the supervision of entities operating in the sector. There are also Acts that control certain lines of insurance business and duties, such as the Marine Insurance Act of 1963 and the Public Liability Insurance Act of 1991.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Billion):

Iron Deficiency
CKD (Chronic Kidney Disease)
Sickle Cell
Aplastic
Others

By Drugs

Dietary Supplements
Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacy
Store Pharmacy
Online
Others

The distribution channel for anemia drugs in India is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.